Subscribe
Ergomed's position in high-growth niches makes it a UK biotech standout
Biffa's resources man times his sale well
Founder and chief exec sells down but remains largest shareholder
Superdry chief exec looks past current concerns
Only a fool would invest in something as cyclical as recruitment as we hurtle towards a recession. And yet鈥�
While geographic diversification makes sense, tough macro conditions make the Peru-focused miner鈥檚 life that much harder
The launch of its new drug could herald the beginning of a new era for the US biotech
Tempting drinkers who grew a taste for cheap supermarket beer back into pubs has not been an easy task. Michael Fahy reports
Two non execs take a tipple on share price weakness
Our Best of British screen has had a howler over the last year. Is it focusing on the wrong things?
.jpg?source=specialist-ic-stream)
